Imputing gene expression from selectively reduced probe sets

Yoni Donner¹, Ting Feng², Christophe Benoist² & Daphne Koller¹

Measuring complete gene expression profiles for a large number of experiments is costly. We propose an approach in which a small subset of probes is selected based on a preliminary set of full expression profiles. In subsequent experiments, only the subset is measured, and the missing values are imputed. We developed several algorithms to simultaneously select probes and impute missing values, and we demonstrate that these ‘probe selection for imputation’ (PSI) algorithms can successfully reconstruct missing gene expression values in a wide variety of applications, as evaluated using multiple metrics of biological importance. We analyze the performance of PSI methods under varying conditions, provide guidelines for choosing the optimal method based on the experimental setting, and indicate how to estimate imputation accuracy. Finally, we apply our approach to a large-scale study of immune system variation.

Gene expression profiling is commonly used to study regulatory mechanisms¹ and to obtain a comprehensive view of cellular state². Both microarrays³ and RNA sequencing offer powerful approaches to profile the transcriptome. However, they become problematic when experimental variables vary along multiple dimensions—such as with strains or individuals assayed⁴–⁶, cell types⁷–¹⁰, heterogeneous tumor samples¹¹, environmental conditions¹², chemical perturbations (for example, drugs⁸) at different doses, genetic perturbations¹³,¹⁴ or different time points¹⁵–¹⁹—because the number of measurements grows combinatorially. The financial cost of genome-wide assays in experiments varying in even two dimensions is typically prohibitive.

An alternative approach¹,⁸,²⁰,²¹ exploits redundancy to reduce costs by measuring a small subset of ‘signature probes’ cheaply using technologies such as bead assays²², reverse transcriptase–PCR²³,²⁴, direct multiplexed measurement²⁵, microfluidic dynamic arrays²⁶ or hybrid selection²⁷. The information loss is balanced by the ability to perform more experiments. Such signatures can be used to estimate similarity between samples¹⁴ or to infer a notion of cellular state¹.

Our PSI approach uses measurements of selected probes to impute a target expression profile (Fig. 1). Broad imputation from a set of single-nucleotide polymorphisms is used ubiquitously in genome-wide association studies, but to our knowledge this idea has not been previously used with gene expression data. Limited imputation has been performed previously without probe selection to fill in a few missing measurements (usually up to 20%) interspersed in the gene expression matrix²⁸–³¹. Selection of small probe subsets was also proposed for classifying future samples³² (for example, as different disease states or outcomes²¹,³³). Our approach couples probe selection and imputation, simultaneously selecting a probe subset and learning a predictive model of genome-wide expression from measurements of the selected probes. Probes are selected to maximize imputation accuracy using a training set of genome-wide profiles. As with standard genome-wide expression measurements, imputed profiles can be used to infer cellular state, identify differentially expressed genes, compare samples or identify genes with similar expression profiles.

Our tests demonstrate that PSI is effective and accurate in a wide variety of settings, using multiple performance metrics of biological importance on relative and absolute scales. Furthermore, we provide guidelines for applying PSI in new experiments and an analysis of its trade-offs. The PSI software is freely available at http://ai.stanford.edu/~yonid/psi-1.0.zip.

RESULTS

Methods overview

We designed and implemented 15 PSI methods based on established statistical theory (Supplementary Note). In initial comparisons using five data sets, we identified three methods that dominated performance on all data sets (Supplementary Fig. 1 and Supplementary Results). Our in-depth analysis below includes these three leading methods (referred to as ‘PSI methods’) and two simple methods as baselines for comparison (Table 1a and Online Methods).

Locally weighted averaging (LWA) uses sample similarity to impute probe measurements within new samples as weighted averages of the entire training set. Weights are based on similarities computed using the selected probes, and probes are chosen incrementally to minimize the imputation error using leave-one-out cross-validation. The regularized Gaussian estimation (RGE) family of methods models the joint expression of all probes as a

¹Department of Computer Science, Stanford University, Stanford, California, USA. ²Department of Microbiology and Immunobiology, Division of Immunology, Harvard Medical School, Boston, Massachusetts, USA. Correspondence should be addressed to D.K. (koller@cs.stanford.edu).

RECEIVED 11 APRIL; ACCEPTED 4 SEPTEMBER; PUBLISHED ONLINE 14 OCTOBER 2012; DOI:10.1038/NMETH.2207
methods focused on probes showing meaningful variation (referred to as ‘target probes’), as imputation is trivial for probes whose training set expression level is nearly constant. We evaluated performance using cross-validation, assessing imputation quality for samples not seen in the training set relative to the measured ground-truth complete expression profiles. The primary evaluation metric consisted of Pearson correlation coefficients (PCCs) between imputed and measured levels for each probe over the test set (ground-truth PCC, or gtPCC). Additional metrics were used to evaluate the identification of differentially expressed probes for selection and the clustering of probes and samples.

**PSI is effective and accurate**

gtPCC values for PSI methods significantly exceeded those for baselines on all data sets, for any number of selected probes between 5 and 300 (Fig. 2a and Supplementary Fig. 2; \( P < 10^{-100}, t\)-test). The imputations were accurate throughout the range of values seen in the data (Fig. 2b), and the improvements over baselines were uniform across all PCC values (Supplementary Fig. 3). To evaluate accuracy, we compared imputation error (\( E \)) to the underlying noise in the data by estimating the variance between biological replicates (\( V \)) available for three data sets. Imputation errors were computed after averaging \( K \) replicates, which reduced their variance by \( K \), allowing separate estimation of the total imputation error (\( E + V/K \)) and \( E/V/K \) was comparable to \( V \) on CMap (\( K = 2 \), Cohen’s \( d = 0.7585 \)) and imm (\( K = 3 \), Cohen’s \( d = -0.4974 \)) and notably smaller than \( V \) on age (\( K = 5 \), Cohen’s \( d = 1.8926 \)), implying high accuracy relative to the data set–specific noise (Fig. 2c).

We next analyzed performance using additional metrics of biological importance, starting with identification of differential expression (Online Methods), evaluated on four data sets using 5–300 selected probes (Fig. 3a). PSI methods outperformed baselines with overall high accuracy (\( P < 10^{-6} \) for all comparisons except LWA versus NN on CMap, paired \( t \)-tests), but between–data set variability was considerable: on CMap, imm and TCGAg, PSI methods (RGE in particular) achieved good results on absolute scales, with medians above 0.9 and over 80% of sample area-under-curve values above 0.8 (Fig. 3b), whereas on...
Supplementary Fig. 4

Figure 2 | Relative and absolute imputation accuracy. (a) Median Pearson correlation coefficients between imputed and measured expression levels (gtPCCs) using 5–300 selected probes for eight data sets. Error bars, s.e.m.; \( n \) = number of target probes – number of selected probes. (b) Density heat maps comparing imputed and measured expression for representative data sets and numbers of selected probes. Colors represent local probe density. Blue contour lines represent regions of equal density. (c) Comparison of imputation error with variance in biological replicates. Top: density heat maps of probe-specific intrareplicate variance versus imputation error. Bottom: the distribution of intrareplicate variance (green curve) and imputation errors (purple curves) for varying numbers of selected probes.

pom the median was 0.68. This variability emphasizes that imputations are predictions with confidence levels that depend on signal-to-noise ratios of the training set data. Clustering of gene expression is commonly used to analyze probe correlation structure. We directly evaluated probe-probe correlations (PPCs) between the measured and imputed correlation matrices (Online Methods). As a baseline, we computed PPCs between training and test-set empirical correlation matrices (trPPCs) to represent data set–specific variability in correlation structures. The PSI methods RGE and SR were far superior to baselines (Fig. 3c) and also exceeded trPPCs with 50 or more selected probes, whereas CR was significantly below trPPCs, and NN was inconsistent, suggesting that the imputations accurately preserved similarity structures between probes (\( P < 10^{-6} \) for all comparisons, paired \( t \)-tests). The correlations were preserved across all PCC values (Supplementary Fig. 4). Sample-sample correlations (SSCs), defined analogously to PPCs, were also evaluated. CR performed better and LWA worse than with other metrics; RGE and SR led on high-performance data sets, with performance above the tagSSC baseline, which uses selected rather than imputed probes. On low-performance data sets, CR and tagSSC were better (Supplementary Fig. 5 and Supplementary Results).

Guidelines for applying PSI

Next, we estimated the accuracy of PSI methods by using the median of the distribution of intrareplicate variance (green curve) and imputation errors (purple curves) for varying numbers of selected probes. Another trade-off exists for RGE methods, in which estimating covariance matrices for full expression profiles requires considerable computational resources. We developed a lower-complexity approximation (modular decomposition, MD) by estimating covariance matrices over disjoint subsets (modules) of correlated genes (Supplementary Note). The number of modules trades off accuracy and computational resources because using more modules implies stronger assumptions on the probe covariance structure. Accuracy decreased with increasing modularity on data sets with high overall performance (Fig. 4c) because of information loss across module boundaries, but accuracy can improve if overall performance is low by focusing on highly predictive intramodular interactions (\( r = -0.737 \) between gtPCC changes with increasing modularity and predicted performance; Online Methods). Computational demands typically increase and overall accuracy decreases with increasing numbers of target probes, making MD useful in high-dimensional imputation tasks.

Next, we addressed the choice of PSI method. Among LWA, RGE and SR, the best-performing method depended on the number of selected probes, target probes and training set samples and on data set ‘linearity’ measured as the fraction of the variance explained by the principal eigenvector of the matrix of interprobe correlations (Online Methods). To predict PSI performance according to the data set and number of selected probes, we used the logarithm of the product of the ratio of selected probes to target probes, the number of training samples, and linearity (samples, probe ratio, linearity: SPRL). More complex predictors could assign weights to these components, but SPRL is simple and intuitive and requires no parameter fitting.

We evaluated SPRL using a relative performance metric which assigns scores between 0 and 1 per probe (Online Methods). SPRL predicted the best-performing methods well (Fig. 5a), with LWA leading for SPRL below –1, RGE and SR leading for SPRL above 1, and a transition from LWA to the linear methods between −1 and 1 (Spearman’s rho between SPRL and relative performance: LWA,
Figure 3 | Additional evaluation metrics of biological relevance. (a) Area under receiver operating characteristic curve (AUC) values for identifying differentially expressed probes in a new sample as a function of the number of selected probes. Error bars, s.e.m.; n = 1,211 (CMap), 349 (imm), 386 (TCGAg), 42 (pom). (b) Cumulative distribution function plots in which, for each AUC value, the corresponding y-axis value is the fraction of samples with an AUC above that value. (c) Preservation of probe correlation structure is indicated by PPC as a function of the number of selected probes. The black curve corresponds to trPPC, the PPC value with correlations estimated using the training set.

Figure 4 | Cost-benefit analysis to determine the optimal number of selected probes and modular decomposition subsets. (a) Mean improvement in overall performance (gtPCC) with an additional selected probe, measured as the slope of the regression line for gtPCC by number of selected probes. Error bars, standard error of the slope. (b) Density heat maps of PCC values using 2k versus k selected probes (k = 50, 100, 150) for three PSI methods (n > 60,000 comparisons for each subpanel). (c) gtPCC versus number of selected probes for various numbers of modules. Lighter greens, more modules. Error bars, s.e.m.; n = number of target probes – number of selected probes.

Figure 5 | PSI applied to ImmVar data

We applied PSI to select probes in the ImmVar Project (http://www.immvar.org/), a collaborative study of the impact of human genetic variation on the expression of immune genes in individuals with no known immunologic, inflammatory or infectious disease. Because of the large number of samples (Online Methods), our goal was to define a reduced probe set for signature genes that could be assayed using NanoString25 and used to give global expression profiles by imputation. We assembled a 58-sample training set from two independent microarray data sets and used a filter based on minimal expression and variation to reduce the number of probes to 2,175. Of these, 63 probes of interest were chosen in advance, and PSI was used to select an additional 187 for a total of 250 signature probes (Online Methods).

The high linearity of this data set (0.35) suggested that linear methods would perform well despite the large number of target probes relative to the number of samples. We selected probes and trained models for LWA, RGE and SR. A test set of 45 new microarray samples that encompassed genetic variation and T-cell activation was then generated (Online Methods).

We compared the imputed expression values to those measured in the test set across the 2,175 target probes. The linear expression was −0.740; RGE, 0.717; SR, 0.567). Because LWA is nonlinear and nonparametric, it can generate better predictions than parametric methods when very little information is available to estimate parameters (as with few samples or low probe ratio).

SPRL also predicted overall imputation accuracy (Fig. 5b) without the need to run computationally intensive cross-validation experiments (Spearman’s rho between SPRL and gtPCC: LW A, 0.485; RGE, 0.735; SR, 0.743). The individual components of SPRL were less accurate predictors (Supplementary Table 1).
method accuracies were very high, with PCC modes above 0.95 (Fig. 5c,d), demonstrating that probe selection successfully identified the probes whose expression levels are most informative about the target probes, and imputation reconstructed the target expression profiles with high precision using only those selected probes. Notably, probes selected in one data set were used to generate high-accuracy imputations on a different (but related) data set. The probes selected by RGE are now being used by the ImmVar Project for activated−T-cell experiments.

DISCUSSION
PSI can be applied when a training set can be assembled under conditions that are similar for subsequent experiments. The ImmVar results demonstrate that moderate similarity between the training set and subsequent experiments is sufficient to produce highly accurate imputations. Furthermore, imputation from the selected probes predicted the mean of biological replicates with high precision using only those selected probes. Notably, probes selected in one data set were used to generate high-accuracy imputations on a different (but related) data set. The probes selected by RGE are now being used by the ImmVar Project for activated−T-cell experiments.

Imputation error is low on average, but researchers may consider certain target probes especially important. Individual-probe imputation errors can be weighed accordingly by a straightforward modification to the PSI objective function. Additionally, we analyzed probe characteristics based on imputation error, demonstrating that high imputation errors are strongly associated with measurement errors but not with gene functional classification (Supplementary Fig. 6 and Supplementary Results) and thus supporting the robustness of PSI.

Applying PSI to a new application requires choosing a method and a number of probes to select. SPRL accurately positions applications on an axis that intuitively corresponds to prediction difficulty, making it a valid tool for choosing a PSI method. Computational demands also influence method choice. PSI methods scale well, except RGE, for which we propose using modular decomposition as an approximation. Full time and space complexity analyses are given in the Supplementary Note. Because the number of selected probes trades off cost and accuracy, data alone cannot define an optimal number. SPRL can help estimate overall imputation accuracy and choose a method given the number of selected probes.

Data set characteristics strongly separate LWA from RGE and SR. LWA can model nonlinear relationships, making it more suitable for low-linearity data sets. RGE and SR are parametric, and their accuracy depends on the number of parameters to be estimated (which increases with more target probes) and the amount of training data (which increases with more samples). LWA exploits global similarities in expression patterns, whereas RGE and SR exploit local relationships between probes. Inferring the global state requires fewer probe measurements than estimating many individual local relationships, which explains why LWA produces better imputations using very few probes but, as additional probes are measured, RGE and SR improve more rapidly using information on finer scales. This also explains why using MD to reduce the number of parameters that need to be estimated is most useful when the learning problem is difficult, as effectively captured by SPRL. Conversely, with sufficient information available to estimate a higher-complexity model, reducing the number of parameters decreases performance.

To examine whether SR and RGE are limited by their linear nature, we developed a nonlinear parametric method based on estimating a mixture model (Supplementary Results). This method was inferior to the linear methods (Supplementary Fig. 7), suggesting that the disadvantage of the linear methods in the low-performance settings is likely due to the difficulty of estimating a large number of parameters from noisy data with few observations rather than due to nonlinear relationships between probes.

Although some of our imputation methods are based on statistical foundations similar to those of previous work (principal component analysis29,30 and linear regression28,31), the three leading methods were developed in our current study. The PSI paradigm is the first to propose a tight integration between selection and imputation based on a unified objective. Our proposed solution consists of multiple methods, suitable for a wide range of applications, along with criteria for choosing among them. Imputation uses information from the selected probes to predict target probe expression with accuracy comparable to the similarity between
biological replicates. These characteristics make PSI a valuable new tool for understanding cellular networks and their variations.

**Methods**

Methods and any associated references are available in the online version of the paper.

**Accession codes.** Accession codes and links for the data used in this paper are listed in the Online Methods.

Note: Supplementary information is available in the online version of the paper.

**Acknowledgments**

This work was supported by grant RC2 GM093080 (funded through the American Recovery and Reinvestment Act) from the US National Institutes of Health—National Institute of General Medical Sciences to C.B. and D.K. We thank I. Amit and J. Ye for useful comments on this manuscript.

**Author Contributions**

Y.D. and D.K. designed the methods; Y.D. implemented the methods, wrote the code, performed the experiments and analyzed the data; T.F. and C.B. provided data and gave feedback on the results; Y.D. and D.K. wrote the manuscript; C.B. reviewed and commented on the manuscript.

**Competing Financial Interests**

The authors declare no competing financial interests.

Published online at http://www.nature.com/doifinder/10.1038/nmeth.2207. Reprints and permissions information is available online at http://www.nature.com/reprints/index.html.

1. Amit, I. et al. Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Nature 326, 257–263 (2009).
2. Golub, T.R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531–537 (1999).
3. Schena, M., Shalon, D., Davis, R.W. & Brown, P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467–470 (1995).
4. Cheung, V.G. et al. Natural variation in human gene expression assessed in lymphoblastoid cells. Nat. Genet. 33, 422–425 (2003).
5. Schadt, E.E. et al. Genetics of gene expression surveyed in mouse, maize and man. Nature 422, 297–302 (2003).
6. Eilsson, V. et al. Genetics of gene expression and its effect on disease. Nature 452, 423–428 (2008).
7. Su, A.I. et al. Large-scale analysis of the human and mouse transcriptomes. Proc. Natl. Acad. Sci. USA 99, 4465–4470 (2002).
8. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006).
9. Lein, E.S. et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445, 168–176 (2007).
10. Dimas, A.S. et al. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 325, 1246–1250 (2009).
11. Alizadeh, A.A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000).
12. Gasch, A.P. et al. Genomic expression programs in the response of yeast cells to environmental changes. Mol. Biol. Cell 11, 4241–4257 (2000).
13. Wagner, A. Estimating coarse gene network structure from large-scale gene perturbation data. Genome Res. 12, 309–315 (2002).
14. Hughes, T.R. et al. Functional discovery via a compendium of expression profiles. Cell 102, 109–126 (2000).
15. Whitfield, M.L. et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol. Biol. Cell 13, 1977–2000 (2002).
16. Chu, S. et al. The transcriptional program of sporulation in budding yeast. Science 282, 699–705 (1998).
17. Cho, R.J. et al. A genome-wide transcriptional analysis of the mitotic cell cycle. Mol. Cell 2, 65–73 (1998).
18. Spellman, P.T. et al. Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization. Mol. Biol. Cell 9, 3273–3297 (1998).
19. Dekisi, J.L., Iyer, V.R. & Brown, P.O. Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 278, 680–686 (1997).
20. Pomeroy, S.L. et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436–442 (2002).
21. van ‘t Veer, L.J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
22. Bibikova, M. et al. Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am. J. Pathol. 165, 1799–1807 (2004).
23. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
24. Bustin, S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25, 169–193 (2000).
25. Geiss, G.K. et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 26, 317–325 (2008).
26. Spurgeon, S.L., Jones, R.C. & Ramakrishnan, R. High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS ONE 3, e1662 (2008).
27. Gnarke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 27, 182–189 (2009).
28. Xing, E.P., Jordan, M.I. & Karp, R.M. Feature selection for high-dimensional genomic microarray data. in Proc. Int. Conf. Mach. Learn. (eds. Brodley, C.E. & Pohorecky) Danyluk, A.) 601–608 (ICML 2001).
29. Hedenfalk, I. et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344, 539–548 (2001).
30. Troyanskaya, O. et al. Missing value estimation methods for DNA microarrays. Bioinformatics 17, 520–525 (2001).
31. Heng, T.S.P. et al. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol., 9, 1091–1094 (2008).
32. Uba, S. et al. A Bayesian missing value estimation method for gene expression profile data. Bioinformatics 19, 2088–2096 (2003).
33. Kim, H., Golub, G.H. & Park, H. Missing value estimation for DNA microarray gene expression data: local least squares imputation. Bioinformatics 21, 187–198 (2005).
34. Ba, T.H., Dysvik, B. & Jonassen, I. LSimpute: accurate estimation of missing values in microarray data with least squares methods. Nucleic Acids Res. 32, e34 (2004).
35. Scherf, U. et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 26, 236–244 (2000).
36. Liu, X. et al. Analysis of cell fate from single-cell gene expression profiles in C. elegans. Cell 139, 623–633 (2009).
37. Zahn, J.M. et al. AGENMAP: a gene expression database for aging in mice. PLoS Genet. 3, e201 (2007).
ONLINE METHODS

Software and data. A command-line tool implementing the three leading methods described in our paper (LWA, RGE and SR), with full documentation, is available in the Supplementary Software and at http://ai.stanford.edu/~yonid/psi-1.0.zip. The data sets used in this paper, in the format used by this tool, are included in Supplementary Data.

Data sets and processing. We used the following data sets for evaluation of the methods:

NCI60 (ref. 34) data were retrieved from http://discover.nci.nih.gov/nature2000/data/selected_data/t_matrix1375.txt; this set comprises 1,375 genes and 60 cell lines.

Yeast stress data12 were retrieved from http://gasch.genetics.wisc.edu/datasets.html. The full data set contains 6,152 genes and 173 conditions. We also used a ‘filtered Gasch’ data set with only the 788 probes with the highest variance. We refer to the full data set as ‘fg’ and to the filtered one as ‘Gasch’.

WormDB35 data were retrieved from http://cmgm.stanford.edu/~kimlab/public_html/Liouetal/index.html and contain 93 genes and 363 tissues. We used Supplementary Table 4 (http://download.cell.com/mmcsc/journals/0092-8674/PIIS0092867490011180.mmc6.zip) from ref. 36. We refer to this data set as ‘worm’.

AGEMAP covers 8,932 genes in 16 tissues. We retrieved Supplementary Table 4 from http://cmgm.stanford.edu/~kimlab/aging_mouse/mouse_downloads.htm. We used all 16 tissues and included only the probes reported by the authors as significantly age-related from Table S5 (http://www.plosgenetics.org/article/fetchSingleRepresentation.action?uri=info:doi/10.1371/journal.pgen.0030201.st005). There are 128 samples overall (8 mice, 16 tissues) with several biological replicates for each (usually 5). We averaged all the replicates to get the final data set of 314 probes and 128 samples. We refer to this data set as ‘age’.

Breast cancer data from 78 patients31 were retrieved from http://bioinformatics.nki.nl/data/van-t-Veer_Nature_2002/2. The initial step of processing used originally is the selection of about 5,000 genes that were significantly regulated across the group of samples, defined as “more than two-fold regulation and significance of regulation p < 0.01 in more than 5 experiments” (Supplementary Methods in ref. 21). We applied these criteria and used the resulting data set, which has 4,918 probes and 78 samples. We refer to this data set as ‘vv’. The paper also identifies a breast cancer signature using 231 probes. The list of probes is provided in the supplementary information (Table S2, http://www.nature.com/nature/journal/v415/n6871/extref/415530a-s9.xls). We also included the signature-only data set of 231 probes and 78 samples and refer to it as ‘vsgv’.

The paper on central nervous system embryonal tumors30 includes several data sets, available from http://www.broadinstitute.org/mpr/CNS/. We used ‘Data Set A’, which includes 42 samples and is available from http://www.broadinstitute.org/mpr/publications/projects/CNS/Pomeroy_et_al_0G04850_11142001_datasets.zip. We performed the preprocessing steps of rescaling to account for different chip intensities, thresholding and applying variation filters, as described in http://www.broadinstitute.org/mpr/publications/projects/CNS/Pomeroy_et_al_0G04850_11142001_supppl_info.doc. This resulted in 4,267 probes and 42 samples. We refer to this data set as ‘pom’.

The Immunological Genome37 includes gene expression profiles of cells in the immune system of mice. The raw CEL files were downloaded from Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/), accession number GSE15907, and normalized. The full data set has 35,512 probes and 349 samples. A variance filter was applied to select the 1,771 probes with the highest variance. After averaging biological replicates, the data set has 1,771 probes and 126 samples. We refer to this data set as ‘imm’.

Connectivity Map8 is a data set generated at the Broad Institute. We used version 2, which contains 6,100 instances overall. We processed the data as follows. We downloaded the raw CEL files from http://www.broadinstitute.org/cmap/ and normalized them. From each drug-perturbation sample, we subtracted the mean of the control experiments corresponding to that sample (in log space). We used instances for only the MCF7 cell type (for which there is the largest number of instances) and the highest concentration available for each drug. We averaged the expression over biological replicates where available. These steps left us with 1,211 samples, each one corresponding to the averaged differential expression of the highest concentration of a single drug relative to its control experiments. Next, we filtered the probes to include only probes whose expression changed at least threefold under at least five drugs. The resulting data set, to which we refer as ‘CMap’, has 1,052 probes and 1,211 samples.

We generated two data sets using The Cancer Genome Atlas. The first uses microRNA expression from the experiment titled ‘MicroRNA Analysis of TCGA GBM samples using Agilent MicroRNA array’. Data were retrieved using the TCGA Data Portal at https://tcga-data.nci.nih.gov/tcga/. This data set, to which we refer as ‘TCGAm’, includes 534 probes and 379 samples. The second data set based on TCGA includes all gene expression samples for GBM generated using the HT_HG-U133A chip. The experiment title is ‘TCGA Analysis of RNA Expression for Glioblastoma Multiforme Using Affymetrix HT_HG-U133A’. These data were also retrieved using the TCGA Data Portal. We used only the 601 genes that were selected for the first round of glioblastoma multiforme (GBM) tumor sequencing. This list is available from http://ai.stanford.edu/~yonid/GBM_Phase1.txt. Genes were matched to probes by name: exact matches were found for 546 genes, and only those were included. This data set, to which we refer as ‘TCGAg’, includes 546 probes and 386 samples.

These data sets vary in their sample variance, measurement methods and numbers of genes and samples, allowing the comparison of the methods under different settings.

PSI methods. Following is a brief description of the selection and imputation processes of the leading and baseline PSI methods. ‘Greedy selection’ means that probes are selected incrementally, with each subsequent probe selected to minimize the imputation error when using cross-validation on the training set with the previously chosen probes together with the newly added one. Full mathematical and implementation details for all 15 methods are available in the Supplementary Note.

In cluster representatives (CR), the data are clustered using the k-means algorithm with multiple random restarts to l clusters, and from each cluster, a representative probe is chosen such that
the average distance to all probes in the cluster is minimized. Imputation is done simply by using the value of the representative for the entire cluster.

In k nearest neighbors (kNN and NN), probes are greedily selected. Imputation is done by finding the k nearest neighbors in the training set (measured by Euclidean distance using only the selected probes) and averaging them. With k = 1, this method is the baseline ‘nearest neighbor’ (NN).

In locally weighted averaging (LWA), imputations are weighted averages \( \sum_w X_i \) of the entire training set, with weights based on the Euclidean distance, measured on the observed probes, between the training sample and the new sample: \( w_i \propto \exp(\gamma||X_i - X_{new}||^2) \) with \( \sum_w = 1 \). Probes are selected greedily together with the parameter \( \gamma \). We also used a variant (Supplementary Note) in which each probe has its own kernel width.

Regularized Gaussian estimation (RGE) is a family of methods which consist of learning a generative Gaussian model of the training data using one of several estimation methods described below. Probes are greedily selected to minimize the remaining variance of the target probes (which is equivalent to the expected imputation error), conditioned on the probes already selected: \( \text{tr}(\Sigma_{tt} - \Sigma_{tt}^{-1}\Sigma_{st}) \), where \( \Sigma_{tt} \) is the estimated covariance between the target probes, \( \Sigma_{st} \) is the estimated covariance between the selected probes, and \( \Sigma_{tt} \) is the estimated covariance between the selected and the target probes. Imputation is done by computing the expected value of the unobserved probes given the observed ones in the Gaussian model. We used the ‘L2Cov’ variant.

In structured regression (SR), imputations are linear combinations of the selected probes. The regression weights are learned simultaneously with the selection of probes by using a structured prior based on the \( L_{1,\infty} \) norm that yields solutions with many zero weights, corresponding to unselected probes.

**RGE covariance estimation variants.** RGE methods estimate a Gaussian distribution over full expression profiles using the training data. Probe are selected to minimize the prediction error in the model. Imputation is done by computing the conditional expected value of the unobserved probes given the observed ones in the Gaussian model. We developed several variants to estimate the covariance matrix:

- PCAC is a probabilistic PCA model estimated on the training data. The number of principal components is chosen by cross-validation. An alternative method based on PCA was also developed, which does not belong in the RGE family. This method, PCAR, uses PCA regression (Supplementary Note).
- SCSS, the unbiased maximum-likelihood estimate of the covariance matrix is shrunk toward a diagonal covariance matrix, with the shrinkage coefficient determined analytically. In another variant, SCECV, the shrinkage coefficient is chosen using cross-validation (Supplementary Note).
- In L1Cov, a sparse precision matrix (the inverse of the covariance matrix) is estimated using \( L_1 \) regularization. L2Cov is similar, but it uses \( L_2 \) regularization on the precision matrix. L2Cov is the variant that was chosen to represent the entire RGE family (Supplementary Note).
- In soft modular Gaussian (SMG), the precision matrix is estimated using \( L_2 \) regularization, in which the variance of the Gaussian prior for each entry in the precision matrix depends on the Pearson correlation between the corresponding probe pair (Supplementary Note).

**Regression variants.** RGE methods use Gaussian generative models for the gene expression data and then select probes and impute using the learned models. Regression methods are discriminative and do not model the distribution over the selected probes. They predict the expression of the unobserved probes as linear combinations of the observed ones. Greedy regression (GR) methods use a stepwise procedure to select probes to minimize the imputation error. Structured regression (SR) methods use sparse priors on the regression weights such that only few probes have nonzero weights in the model, which correspond to selected probes. We evaluated several variants, differing mostly in regularization.

L2Reg is the only GR variant, and it uses \( L_2 \) regularization for learning the weights. Selection is done with a greedy algorithm because \( L_2 \) regularization does not result in sparse weights.

GL2 and L1Inf are SR variants and yield regression models that are sparse in the number of probes which have nonzero weights. GL2 uses a block-\( L_1 \) norm, whereas L1Inf uses the \( L_{1,\infty} \) norm over the regression weights during the selection phase. The L1Inf variant represents the regression family.

**ImmVar data.** The ImmVar study involves a cohort of 600 blood donors of African American, Asian and Caucasian ancestry. In the expression component of the project, genome-wide expression profiling is performed on highly purified naïve CD4+ T lymphocytes and CD14+CD16− monocytes. In the activation component, CD4+ T cells and monocyte-derived dendritic cells from different individuals are activated in vitro to measure the activation response of these two cell types. The activation component involves a large number of samples, which vary across individual, ligand, cell type and time point. As genome-wide expression profiling this many samples would be economically impossible, we elected to use PSI to define a set of 250 signature genes from a limited number of microarrays.

We first assembled a training set from two independent data sets (see below). The first, which provided a component of genetic variability, was generated from resting CD4+ T lymphocytes from the peripheral blood of 31 individuals, encompassing both genders and the three ancestries. The second data set corresponded to transcriptional changes elicited during a time-course analysis of T-cell activation. It was generated by activating blood CD4+ T cells (pooled from four donors of mixed gender and ethnicity) with beads coupled with anti-CD3 and anti-CD28 in culture for different periods of time (0, 0.75, 2, 4, 10, 24, 48 and 72 h). There were 58 samples in the training set.

The test set was generated by profiling purified CD4+ T cells from 15 different individuals (covering all ethnic and gender groups), similarly activated for 4 h and 48 h, thus encompassing both early and late phases of the T-cell response. This test set simultaneously encompasses genetic variation and cell activation.

**ImmVar processing.** For profiling of purified CD4+ T cells, blood peripheral blood mononuclear cells were isolated by Ficoll density-gradient centrifugation and stained with monoclonal antibodies reactive to CD3/4/8/14/16/19/25/62L and CD3+CD4+CD62Lhi cells were purified to >99% purity by two rounds of flow
cytometric sorting on a FACS Aria. 50,000 cells were sorted directly into Trizol for RNA preparation. Isolated RNA was amplified and prepared for hybridization to the Affymetrix HuGene ST1.0 Array using the GeneChip Whole Transcript (WT) Sense Target Labeling Assay. Raw data were normalized using the Robust Multichip Average algorithm in the 'Expression File Creator' module in GenePattern.

For profiling of activated cells, CD4+ T cells were isolated from whole blood by negative selection using RosetteSep human CD4+ T cell enrichment cocktail and RosetteSep density medium gradient centrifugation, then cells were stored frozen. On the day of activation, CD4+ T cells from 15 individuals were thawed, resuspended in RPMI supplemented with 10% FCS and plated at 50,000 cells per well in a 96-well plate. Cells were either left untreated as a baseline control or stimulated with bead-bound anti-CD3 and anti-CD28 at a bead-to-cell ratio of 1:1 for 4 h or 48 h. At each time point, a second step of purification of CD4+ T cells was performed, with magnetic positive selection using the Invitrogen Dynal CD4 positive isolation kit (96-well format) before Trizol extraction of RNA and microarray profiling as above.

Prior to selection, we filtered the probes using two filters: first, probes must have an expression level above 80 in at least 20% of the samples; second, probes must be differentially expressed (defined as twofold change from the geometric mean) in at least 3 out of the 58 samples.

Identifying differential expression. We ranked the imputed expression profiles, generated receiver operating characteristic (ROC) curves for varying thresholds of classifying a probe as differentially expressed, and summarized the curves using the area under curve (AUC) metric. We evaluated different variants of this metric and demonstrated them to be nearly equivalent in terms of ranking (Supplementary Fig. 8 and Supplementary Results). In our main analysis, we focused on the most common case of identifying which probes in a new sample are likely to be differentially expressed, using the common criterion of a twofold change from the mean. After probes with very low variation were filtered out, all remaining probes show a minimal degree of differential expression, but not in every sample. This metric evaluates the ability of a method to predict which probes will be differentially expressed in a new sample.

Statistical analysis. All experiments on the 12 main data sets were performed with fivefold cross-validation, using for the analysis only the values of target probes imputed on the one-fifth of the data used as test set within each split. Results were aggregated over splits by averaging or taking the median (for gtPCC). Method-specific parameters were chosen using cross-validation within the training set (four-fifths of the data). Expression values were centered by subtracting the training set mean within each training-test split. The metrics used were gtPCC, the median PCC over all target probes; [GS/SS]DE[25]AUC, the area under the ROC curve for identifying differentially expressed probes in a new sample or samples in which a given probe is differentially expressed (25 indicates the top 25% were used as differentially expressed rather than twofold change from the mean); PPC/SSC, the PCC between the probe-probe/sample-sample correlation matrix computed on the measured expression and the one computed on the imputations, averaged over cross-validation splits; trPPC, the PPC using the training set instead of the imputations; and tagSSC, the SSC using selected probes instead of using the imputations.

To compute the average improvement per additional probe, we computed the slope of a linear regression line fit to the gtPCC as a function of the number of selected probes, from 50 to 300.

To evaluate the change in imputation accuracy with an increasing number of modules, we first computed, for multiple data sets and numbers of selected probes, Spearman rank-order correlation coefficients between the number of modules used and gtPCCs. The PCC of this measure and a predictor of overall performance (SPRL) was used to assess the relationship between overall accuracy and the accuracy change with increased modularity.

Linearity is computed as the fraction of the variance explained by the first (largest eigenvalue) principal component of the probe-probe covariance matrix. To compute the mean and variance of the linearity estimator, 100 bootstrap iterations were used.

Relative performance is based on the PCC for each probe, by comparing the Fisher transformations of the PCC of each method to the highest-correlated method for that probe by a z score: let $r_{best}$ be the PCC of the best method on a specific probe, and $r$ be the PCC of any method, and then the relative performance for that method is $2\phi((n - 3)^{1/2}(\arctanh(r)−\arctanh(r_{best})))$, where $\phi$ is the CDF of the normal distribution. This relative metric gives a value of 1 to the best-performing method, which continuously decreases to a minimum of 0 as the performance drops farther from that of the best-performing method.